- Cell Biology
- Product Type
- Research Area
- New Products
- About Tocris
- Contact Us
Degraders (e.g.PROTACs, SNIPERs etc), are a new approach for the knockdown of target proteins within cells. Comprising binding moieties for an E3 ubiquitin ligase and a target protein joined by a linker, these hybrid molecules induce selective, proteasome-dependent degradation of target proteins and can be used to investigate downstream effects of protein knockdown or to interfere with specific signaling pathways.
PROTAC is a registered trademark of Arvinas, Inc.
|Cat No||Product Name / Activity|
|(+)-JQ1 based PROTAC with selectivity for BRD4|
|Homo-PROTAC for self-degradation of pVHL30|
|(+)-JQ1 based PROTAC targeting BET bromodomains, active in vivo|
|Potent and selective BRD9 degrading PROTAC|
|Degrades mutant FKBPF36V fusion proteins; useful alternative to genetic methods for target validation|
|TRIM24 degrading PROTAC|
|(+)-JQ1 based PROTAC that selectively degrades BRD4 in cells|
|6532||THAL SNS 032|
|Potent and selective CDK9 degrading PROTAC|
|Multikinase degrading PROTAC|
|Selective ALK Degrader|
|Selective ALK degrader|
|Cat No||Product Name / Activity|
|6155||cis MZ 1|
|Negative Control for MZ1|
|Negative Control for CM 11|
|Negative control for TL 13-112|
|Negative control for TL 13-12|
|Negative control for TL 12-186|
Degraders (e.g.PROTACs, SNIPERs etc), are a new approach for the knockdown of target proteins within cells. Comprising binding moieties for an E3 ubiquitin ligase and a target protein joined by a linker, these hybrid molecules induce selective, proteasome-dependent degradation of target proteins and can be used to investigate downstream effects of protein knockdown or to interfere with specific signaling pathways. The methodology provides an attractive alternative to RNAi methods and have several advantages including:
Another interesting feature of small molecule Degraders is their ability to confer additional selectivity, compared to the profile of the target protein ligand used. This is exemplified by AT 1 (Cat. No. 6356), which selectively degrades BRD4, whereas the target protein ligand component of AT 1, (+)- JQ1 (Cat. No. 4499), inhibits the closely related bromodomains of multiple BET family proteins.
Degraders are pharmacologically characterized by their DC50 and DMax values. These values can be used as a guide for the appropriate starting concentrations to use for your experiment. The DC50 is analogous to traditional IC50 values and is the concentration of Degrader at which 50% of the target protein is degraded. The DMax is the maximum level of degradation achievable.
An important factor to consider when using these products is the timescale required for maximum efficacy. This depends on the individual Degrader used; customers are referred to the references provided for each product for guidance. Another consideration is the 'hook effect', which leads to reduced degradation efficiency when high concentrations of compound are applied to cells. This is due to the formation of binary complexes, that compete with formation of the ternary complexes (E3 ligase-Degrader-target protein) required to achieve degradation. In general, very low concentrations of Degrader are required to achieve effective knock down.
Tocris offers the following scientific literature for Active Degraders to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This brochure highlights the tools and services available from Bio-Techne to support Targeted Protein Degradation research, including:
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
Adapted from the 2015 Cancer Product Guide Edition 3, this poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.
Degraders (e.g. PROTACs) are bifunctional small molecules, that harness the Ubiquitin Proteasome System (UPS) to selectively degrade target proteins within cells. They consist of three covalently linked components: an E3 ubiquitin ligase ligand, a linker and a ligand for the target protein of interest. Authored in-house, this poster outlines the generation of a toolbox of building blocks for the development of Degraders. The characteristics and selection of each of these components are discussed.